Advertisement

Topics

Bioverativ taps new manufacturer as it steps out of Biogen's shadow

04:30 EST 15 Feb 2018 | BioPharmaDive

The spinoff-turned-Sanofi-company could pay more than $100 million to Oxford BioMedica for lentiviral vector production.

Original Article: Bioverativ taps new manufacturer as it steps out of Biogen's shadow

NEXT ARTICLE

More From BioPortfolio on "Bioverativ taps new manufacturer as it steps out of Biogen's shadow"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...